Belantamab Mafodotin Combination Shows Durable Efficacy in Relapsed or Refractory Multiple Myeloma

Source: Pharmacy Times articles

Belantamab mafodotin plus lenalidomide and dexamethasone was found tolerable with no new safety signals and enhanced response rates in patients with multiple myeloma.
Read More